AIDX vs HBIO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AIDX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
HBIO exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 93.5%. While the company maintains a healthy gross margin (57.67%) and a positive operating margin (14.01%), these are completely offset by a devastating net profit margin of -65.51%. High leverage (Debt/Equity of 3.22) and negative revenue growth further compound the risk, suggesting the company is struggling to scale or maintain its market position despite a low Price-to-Sales valuation.
Compare Another Pair
Related Comparisons
AIDX vs HBIO: Head-to-Head Comparison
This page compares 20/20 Biolabs, Inc. (AIDX) and Harvard Bioscience, Inc. (HBIO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.